Results 181 to 190 of about 88,303 (317)

Updated ERNICA guidelines for the management of rectosigmoid Hirschsprung's disease 2025

open access: yesJournal of Pediatric Gastroenterology and Nutrition, EarlyView.
Abstract Objectives To revise the 2018 European Reference Network for rare Inherited and Congenital Digestive and Gastrointestinal Anomalies (ERNICA) clinical guideline for the management of rectosigmoid Hirschsprung's disease (HSCR) based on new evidence and evolving clinical priorities, ensuring continued relevance, trustworthiness, and consistency ...
Daniel Rossi   +35 more
wiley   +1 more source

Hodgkin lymphoma of the ampulla of Vater: A rare cause of obstructive jaundice in children

open access: yesJPGN Reports, EarlyView.
Abstract Hodgkin lymphoma (HL) has a wide spectrum of presentation. Most cases affect lymph nodes (nodal), while extranodal involvement is rare. Whereas the gastrointestinal tract is enriched with lymphoid tissues, the ampulla of Vater is not rich in lymphoid tissue. Involvement of the ampulla of Vater with HL has rarely been reported in adults and has
Sultana Alshammari   +12 more
wiley   +1 more source

Transplantation of the human liver [PDF]

open access: yes, 1985
Iwatsuki, S, Shaw, BW, Starzl, TE
core  

Ocular facial myositis and sialadenitis presenting with new onset ulcerative colitis

open access: yesJPGN Reports, EarlyView.
Abstract Extra‐intestinal manifestations of inflammatory bowel disease (IBD) can involve most organ systems, although the immunologic underpinnings are not well understood. Most patients who present with an extra‐intestinal manifestation have a single site of extra‐intestinal involvement; however, a small cohort presents with multiple different sites ...
Nicole Du, Nicole Mendez, Anil Darbari
wiley   +1 more source

Impact of cystic fibrosis transmembrane conductance regulator modulator therapies on liver stiffness and liver enzymes: An observational perspective single‐center cohort study

open access: yesJPGN Reports, EarlyView.
Abstract Objectives The efficacy of cystic fibrosis transmembrane conductance regulator (CFTR)‐modulator therapies in preventing or ameliorating cystic fibrosis liver disease (CFLD) by correcting CFTR in cholangiocytes is not well‐documented. This study aimed to assess liver function during CFTR‐modulators.
Laura Giugliano   +12 more
wiley   +1 more source

Home - About - Disclaimer - Privacy